WO1999024830A1 - Method for diagnosing alzheimer's disease - Google Patents
Method for diagnosing alzheimer's disease Download PDFInfo
- Publication number
- WO1999024830A1 WO1999024830A1 PCT/US1998/023198 US9823198W WO9924830A1 WO 1999024830 A1 WO1999024830 A1 WO 1999024830A1 US 9823198 W US9823198 W US 9823198W WO 9924830 A1 WO9924830 A1 WO 9924830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- efflux
- channel
- disease
- platelets
- absence
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
Definitions
- Alzheimer's disease is a progressive neurodegenerative disorder which causes irreversible damage to brain cells leading to dementia and ultimately death. It is characterized by formation of amyloid plaques and neurofibrillary tangles in the brain. Currently, it is primarily diagnosed by exclusion of other known causes of dementia. Diagnosis at an early stage prior to irreversible changes is practically non-existent. In order for a therapeutic intervention to be significantly effective, it will have to be administered very early on prior to irreversible changes .
- Mahaut-Smith 8a discloses that blood platelets contain a 30pS conductance charybdotoxin-sensitive channel.
- a 113 pS K + channel sensitive to tetraethylammonium has been described as being absent or not functional in cultured fibroblasts from patients with AD 9 , and this defect was mimicked in normal fibroblasts by the addition of amyloid beta-protein (A ⁇ ) 10 , which is also plentiful in platelets 11 ' 12 .
- a ⁇ amyloid beta-protein
- tetraethylammonium is not a selective inhibitor of K + channels, and so the pharmacological identity of the abnormal channel in cultured fibroblasts is not clear.
- December 3, 1996) discloses a method for the diagnosis of Alzheimer's disease using human cells such as fibroblasts, buccal mucosal cells, neurons, and blood cells such as erythrocytes , lymphocytes and lymphoblastoid cells, wherein the absence of a functional 133 pS potassium channel in the test cells indicates the presence of Alzheimer's disease.
- Tetraethylammonium is employed as a potassium channel blocker to aid in detecting the presence of the functioning 113 pS potassium channel.
- a method for diagnosing Alzheimer's disease which includes the steps of (a) obtaining a sample of platelets from a human subject, and (b) detecting the presence or absence in such platelets of functioning calcium- dependent potassium (Kc a ) channels, the absence of such functioning Kc a channel indicating a positive diagnosis for Alzheimer's disease.
- a potassium channel blocker which has the ability to block the functioning Kc a channel, and may, for example, include apamin, charybdotoxin, or a combination thereof, depending upon the specific functioning calcium- dependent potassium channel involved.
- a method for diagnosing Alzheimer's disease which includes the step of detecting the presence or absence of one or more functioning small-conductance calcium-dependent potassium (SKc a ) channels in blood platelets of a human subject, the absence of a functioning SK_ a channel in such platelets indicating a positive diagnosis for Alzheimer's disease.
- SKc a small-conductance calcium-dependent potassium
- SKc channel blocker which has the ability to block the functioning SKca channel, and may, for example, include apamin, charybdotoxin, or a combination thereof, depending upon the specific SKc a channel involved.
- Detection of the presence or absence of the functional Kc a channel, SKc a channel and/or K Ch channel may be determined by conventional techniques for measuring electrical currents in cells such as the patch clamp technique disclosed by Sakmann, B. et al 28 .
- the presence or absence of the functional potassium channel may also be detected by (1) loading blood platelets with 86 Rb + , (2) stimulating 86 Rb + efflux (from the platelets via K_ a channels) with thrombin or ionomycin, (3) subjecting the thrombin- or ionomycin-stimulated 86 Rb + efflux to the action of an appropriate potassium channel blocker, such as apamin, charybdotoxin or a combination thereof, depending upon the particular functional Kc a channel involved, and (4) determining if the Kc a channel blocker significantly inhibits the thrombin- or ionomycin-stimulated 86 Rb + efflux to cause significant reductions in the 86 Rb + efflux, a lack of
- the potassium channel blocker employed will preferably be apamin or a combination of apamin and charybdotoxin (weight ratio apamin: charybdotoxin from about 4:1 to about 1:1, preferably from about 3:1 to about 1.5:1) .
- the potassium channel blocker employed will be charybdotoxin or a combination of charybdotoxin and apamin (weight ratio charybdotoxin: apamin from about 4:1 to about 1:1, preferably from about 3:1 to about 1.5:1).
- Figures la and lb are graphs showing the effects of apamin and charybdotoxin on thrombin-stimulated 86 Rb + efflux in Control subjects ( Figure la) and in patients with Alzheimer's disease ( Figure lb) ;
- Figures 2a and 2b are graphs showing the effect of -dendrotoxin on thrombin-stimulated 86 Rb + efflux in
- Figures 3a and 3b are graphs showing the effect of apamin and charybdotoxin on ionomycin-stimulated 86 Rb + efflux in Control subjects ( Figure 3a) and in patients with Alzheimer's disease ( Figure 3b).
- Subjects recruited as part of OPTIMA were 14 patients with dementia of the Alzheimer type and 14 non-demented age- and sex-matched controls (details in Table 1) ; each experiment was performed on 11 or 12 of these individuals.
- Platelet perfusion-1 7 - Blood was drawn by venepuncture and anticoagulated with acid-citratedextrose (ACD) . Platelets were prepared by centrifugation within an hour of venesection and incubated with 86 Rb + for 2 h. The platelet suspension (2.5 x 10 7 platelets per ml) was then injected into perfusion chambers, where the cells settled and became immobilized on inert filters (Millipore) .
- Figures 3a and 3b show effect of apamin and charybdotoxin on ionomycin-stimulated 86 Rb + efflux.
- Control sub iects Ionomycin 1 ⁇ M (5-filled circles) increased 86 Rb + efflux over the non- stimulated efflux (1-open circles) .
- Apamin 100 nM (4-open squares) and charybdotoxin 300 nM (3-open triangles) inhibited the stimulated 86 Rb + efflux (P ⁇ 0.0001).
- SK Ca and Kc h channels may not be present at all in AD. However, if that is so, then 86 Rb + efflux must be occurring through other K + channels, since the thrombin-stimulated and ionomycin-stimulated effluxes were quantitatively normal.
- normal human platelets do not contain large-conductance calcium- dependent (BKc a ) channels 21 , and iberiotoxin, a selective inhibitor of BKc channels, had no effect on ionomycin- stimulated effluxes in platelets from any individual (Table 2) , while the only other type of K + channel found in platelets, K v channels 20 ' 21 , responded normally to ⁇ - dendrotoxin.
- K_ a channel abnormalities provide a marker for patients with AD.
- Table 1 Patient data. The data are given as mean (sd) . There were no significant differences between the groups .
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000519782A JP2001523002A (en) | 1997-11-10 | 1998-11-02 | How to diagnose Alzheimer's disease |
CA002308371A CA2308371A1 (en) | 1997-11-10 | 1998-11-02 | Method for diagnosing alzheimer's disease |
AU13716/99A AU750582B2 (en) | 1997-11-10 | 1998-11-02 | Method for diagnosing Alzheimer's disease |
EP98957464A EP1031034A4 (en) | 1997-11-10 | 1998-11-02 | Method for diagnosing alzheimer's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6477997P | 1997-11-10 | 1997-11-10 | |
US60/064,779 | 1997-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999024830A1 true WO1999024830A1 (en) | 1999-05-20 |
Family
ID=22058224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/023198 WO1999024830A1 (en) | 1997-11-10 | 1998-11-02 | Method for diagnosing alzheimer's disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1031034A4 (en) |
JP (1) | JP2001523002A (en) |
AU (1) | AU750582B2 (en) |
CA (1) | CA2308371A1 (en) |
WO (1) | WO1999024830A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077686A2 (en) * | 2000-04-05 | 2001-10-18 | Neurologic, Inc. | Cellular calcium responce for diagnosis of alzheimer's disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401652A (en) * | 1992-07-30 | 1995-03-28 | American Cyanamid Company | Nucleic acid sequence encoding apamin receptor protein |
US5427931A (en) * | 1990-04-24 | 1995-06-27 | Then Regents Of The University Of California | Monoclonal antibody produced against native βamyloid precursor protein |
US5580748A (en) * | 1993-05-03 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic tests for alzheimers disease |
US5670525A (en) * | 1994-08-29 | 1997-09-23 | Bayer Aktiengesellschaft | Substituted 4-phenyl-6-amino-nicotinic acid compounds useful in the treatment of CNS disorders |
US5778893A (en) * | 1991-04-01 | 1998-07-14 | President And Fellows Of Harvard College | Method of diagnosing and monitoring a treatment for Alzheimer's disease |
-
1998
- 1998-11-02 CA CA002308371A patent/CA2308371A1/en not_active Abandoned
- 1998-11-02 AU AU13716/99A patent/AU750582B2/en not_active Ceased
- 1998-11-02 EP EP98957464A patent/EP1031034A4/en not_active Withdrawn
- 1998-11-02 JP JP2000519782A patent/JP2001523002A/en active Pending
- 1998-11-02 WO PCT/US1998/023198 patent/WO1999024830A1/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5427931A (en) * | 1990-04-24 | 1995-06-27 | Then Regents Of The University Of California | Monoclonal antibody produced against native βamyloid precursor protein |
US5778893A (en) * | 1991-04-01 | 1998-07-14 | President And Fellows Of Harvard College | Method of diagnosing and monitoring a treatment for Alzheimer's disease |
US5401652A (en) * | 1992-07-30 | 1995-03-28 | American Cyanamid Company | Nucleic acid sequence encoding apamin receptor protein |
US5607843A (en) * | 1992-07-30 | 1997-03-04 | The American Cyanamid Company | Nucleic acid sequence encoding apamin binding protein |
US5652111A (en) * | 1992-07-30 | 1997-07-29 | American Cyanamid Company | Binding assay utilizing a nucleic acid encoding apamin binding protein |
US5580748A (en) * | 1993-05-03 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic tests for alzheimers disease |
US5670525A (en) * | 1994-08-29 | 1997-09-23 | Bayer Aktiengesellschaft | Substituted 4-phenyl-6-amino-nicotinic acid compounds useful in the treatment of CNS disorders |
Non-Patent Citations (1)
Title |
---|
See also references of EP1031034A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077686A2 (en) * | 2000-04-05 | 2001-10-18 | Neurologic, Inc. | Cellular calcium responce for diagnosis of alzheimer's disease |
WO2001077686A3 (en) * | 2000-04-05 | 2002-08-29 | Neurologic Inc | Cellular calcium responce for diagnosis of alzheimer's disease |
Also Published As
Publication number | Publication date |
---|---|
AU750582B2 (en) | 2002-07-25 |
EP1031034A4 (en) | 2004-11-17 |
AU1371699A (en) | 1999-05-31 |
CA2308371A1 (en) | 1999-05-20 |
EP1031034A1 (en) | 2000-08-30 |
JP2001523002A (en) | 2001-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6087118A (en) | Method for diagnosing alzheimer's disease | |
Mollenhauer et al. | Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration | |
Fei et al. | The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment | |
Sailer et al. | Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus | |
Navaratnam et al. | Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease | |
Zhang et al. | Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: a systematic review and meta-analysis | |
Lauridsen et al. | Cerebrospinal fluid Aβ43 is reduced in early-onset compared to late-onset Alzheimer’s disease, but has similar diagnostic accuracy to Aβ42 | |
JP2015505365A (en) | Methods for diagnosing Alzheimer's disease | |
Gabelle et al. | Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study | |
KR101786859B1 (en) | Method for monitoring clinical and pathological alzheimer's disease using amyloid beta concentration in plasma | |
Dumurgier et al. | CSF Aβ 1-42 levels and glucose metabolism in Alzheimer's disease | |
US5976817A (en) | Diagnostic method for detecting Alzheimer's disease in living patients | |
Hinds et al. | Relationship between serum α1-antichymotrypsin and Alzheimer's disease | |
Tsolaki et al. | Correlation of rCBF (SPECT), CSF tau, and congnitive function in patients with dementia of the Alzheimer's type, other types of dementia, and congrol subjects | |
Schwartz et al. | Plasma concentrations of glutamate and its metabolites in patients with Alzheimer's disease | |
Hall et al. | Biomarkers of basic activities of daily living in Alzheimer's disease | |
WO2008003516A1 (en) | Cell cycle-based blood test to diagnose alzheimer's disease | |
Borroni et al. | Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms | |
Laske et al. | Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients | |
AU750582B2 (en) | Method for diagnosing Alzheimer's disease | |
US20140018299A1 (en) | Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury | |
EP1356299B1 (en) | Method for the diagnosis of alzheimer's disease | |
Lewczuk et al. | Prothrombin concentration in the cerebrospinal fluid is not altered in Alzheimer's disease | |
Řípová et al. | Alterations in Calcium Homeostasis as Biological Marker for Mild Alzheimers Disease? | |
Ling | Vascular and Inflammatory Blood Biomarkers of Cognitive Impairment and Dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2308371 Country of ref document: CA Ref country code: CA Ref document number: 2308371 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13716/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 519782 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998957464 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998957464 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 13716/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998957464 Country of ref document: EP |